Centocor/Five Prime Deal Targets Protein Therapeutics For Osteoarthritis, Pulmonary Fibrosis
This article was originally published in The Pink Sheet Daily
The research and licensing deal with protein-based biotech Five Prime could give the J&J company a therapy for regenerating cartilage.
You may also be interested in...
Collaboration, to be managed by Pfizer's San Francisco-based biotech center, provides pharma giant with antibody targets.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.